Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Histologic Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study.

Miller NJ, Khaki AR, Diamantopoulos LN, Bilen MA, Santos V, Agarwal N, Morales-Barrera R, Devitt M, Nelson A, Hoimes CJ, Shreck E, Assi H, Gartrell BA, Sankin A, Rodriguez-Vida A, Lythgoe M, Pinato DJ, Drakaki A, Joshi M, Velho PI, Hahn N, Liu S, Buznego LA, Duran I, Moses M, Jain J, Murgic J, Barata P, Tripathi A, Zakharia Y, Galsky MD, Sonpavde G, Yu EY, Lyman GH, Grivas P.

J Urol. 2020 Jan 23:101097JU0000000000000761. doi: 10.1097/JU.0000000000000761. [Epub ahead of print]

PMID:
31971495
2.

Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy.

Das S, Ciombor KK, Haraldsdottir S, Pumpalova Y, Sahin IH, Pineda G, Shyr Y, Lin EP, Hsu CY, Chu SK, Goff LW, Cardin DB, Bilen MA, Fisher GA, Wu C, Berlin J.

Oncologist. 2020 Jan 14. doi: 10.1634/theoncologist.2019-0637. [Epub ahead of print]

3.

A Review of Papillary Renal Cell Carcinoma and MET Inhibitors.

Rhoades Smith KE, Bilen MA.

Kidney Cancer. 2019 Nov 1;3(3):151-161. doi: 10.3233/KCA-190058. Review.

4.

Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with checkpoint inhibitors.

Khaki AR, Li A, Diamantopoulos LN, Bilen MA, Santos V, Esther J, Morales-Barrera R, Devitt M, Nelson A, Hoimes CJ, Shreck E, Assi H, Gartrell BA, Sankin A, Rodriguez-Vida A, Lythgoe M, Pinato DJ, Drakaki A, Joshi M, Isaacsson Velho P, Hahn N, Liu S, Alonso Buznego L, Duran I, Moses M, Jain J, Murgic J, Baratam P, Barata P, Tripathi A, Zakharia Y, Galsky MD, Sonpavde G, Yu EY, Shankaran V, Lyman GH, Grivas P.

Cancer. 2019 Dec 12. doi: 10.1002/cncr.32645. [Epub ahead of print]

PMID:
31829450
5.

An intra-tumoral niche maintains and differentiates stem-like CD8 T cells.

Jansen CS, Prokhnevska N, Master VA, Sanda MG, Carlisle JW, Bilen MA, Cardenas M, Wilkinson S, Lake R, Sowalsky AG, Valanparambil RM, Hudson WH, McGuire D, Melnick K, Khan AI, Kim K, Chang YM, Kim A, Filson CP, Alemozaffar M, Osunkoya AO, Mullane P, Ellis C, Akondy R, Im SJ, Kamphorst AO, Reyes A, Liu Y, Kissick H.

Nature. 2019 Dec;576(7787):465-470. doi: 10.1038/s41586-019-1836-5. Epub 2019 Dec 11.

PMID:
31827286
6.

Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy.

Bilen MA, Martini DJ, Liu Y, Shabto JM, Brown JT, Williams M, Khan AI, Speak A, Lewis C, Collins H, Kissick HT, Carthon BC, Akce M, Shaib WL, Alese OB, Pillai RN, Steuer CE, Wu CS, Lawson DH, Kudchadkar RR, El-Rayes BF, Ramalingam SS, Owonikoko TK, Harvey RD, Master VA.

Oncologist. 2019 Dec 5. pii: theoncologist.2019-0751. doi: 10.1634/theoncologist.2019-0751. [Epub ahead of print]

7.

Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.

Martini DJ, Liu Y, Shabto JM, Carthon BC, Hitron EE, Russler GA, Caulfield S, Kissick HT, Harris WB, Kucuk O, Master VA, Bilen MA.

Oncologist. 2019 Dec 5. pii: theoncologist.2019-0578. doi: 10.1634/theoncologist.2019-0578. [Epub ahead of print]

8.

Multidisciplinary Care of Adult Wilms' Tumor During Pregnancy: A Case Report and Review of the Literature.

Brown JT, Harik LR, Barbee MS, Esiashvili N, Badell ML, Goldsmith KC, Master VA, Bilen MA.

Clin Genitourin Cancer. 2019 Oct 2. pii: S1558-7673(19)30290-3. doi: 10.1016/j.clgc.2019.09.021. [Epub ahead of print] No abstract available.

PMID:
31732475
9.

Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials.

Martini DJ, Kline MR, Liu Y, Shabto JM, Williams MA, Khan AI, Lewis C, Collins H, Akce M, Kissick HT, Carthon BC, Shaib WL, Alese OB, Pillai RN, Steuer CE, Wu CS, Lawson DH, Kudchadkar RR, El-Rayes BF, Ramalingam SS, Owonikoko TK, Harvey RD, Master VA, Bilen MA.

Cancer. 2020 Feb 1;126(3):575-582. doi: 10.1002/cncr.32576. Epub 2019 Oct 24.

PMID:
31648379
10.

Hybrid negative enrichment of circulating tumor cells from whole blood in a 3D-printed monolithic device.

Chu CH, Liu R, Ozkaya-Ahmadov T, Boya M, Swain BE, Owens JM, Burentugs E, Bilen MA, McDonald JF, Sarioglu AF.

Lab Chip. 2019 Oct 9;19(20):3427-3437. doi: 10.1039/c9lc00575g.

PMID:
31553343
11.

Management of metastatic renal cell carcinoma: The complexity of choice.

Brown JT, Bilen MA.

EBioMedicine. 2019 Sep;47:2-3. doi: 10.1016/j.ebiom.2019.08.049. Epub 2019 Sep 6. No abstract available.

12.

Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy.

Bilen MA, Shabto JM, Martini DJ, Liu Y, Lewis C, Collins H, Akce M, Kissick H, Carthon BC, Shaib WL, Alese OB, Steuer CE, Wu C, Lawson DH, Kudchadkar R, Master VA, El-Rayes B, Ramalingam SS, Owonikoko TK, Harvey RD.

BMC Cancer. 2019 Aug 29;19(1):857. doi: 10.1186/s12885-019-6073-7.

13.

Reply to Tumor-associated macrophages: "Good cop-bad cop".

Bilen MA, Kissick HT, Harvey RD.

Cancer. 2019 Jun 1;125(11):1942-1943. doi: 10.1002/cncr.32015. Epub 2019 Feb 12. No abstract available.

PMID:
30748009
14.

Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials.

Martini DJ, Liu Y, Shabto JM, Lewis C, Kline MR, Collins H, Akce M, Kissick HT, Carthon BC, Shaib WL, Alese OB, Pillai RN, Steuer CE, Wu CS, Lawson DH, Kudchadkar RR, Master VA, El-Rayes BF, Ramalingam SS, Owonikoko TK, Harvey RD, Bilen MA.

Invest New Drugs. 2019 Dec;37(6):1198-1206. doi: 10.1007/s10637-019-00736-0. Epub 2019 Feb 6.

PMID:
30725388
15.

Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer.

Sonpavde G, Agarwal N, Pond GR, Nagy RJ, Nussenzveig RH, Hahn AW, Sartor O, Gourdin TS, Nandagopal L, Ledet EM, Naik G, Armstrong AJ, Wang J, Bilen MA, Gupta S, Grivas P, Pal SK, Lanman RB, Talasaz A, Lilly MB.

Cancer. 2019 May 1;125(9):1459-1469. doi: 10.1002/cncr.31959. Epub 2019 Jan 8.

PMID:
30620391
16.

MRI quantitation of abdominal skeletal muscle correlates with CT-based analysis: implications for sarcopenia measurement.

Khan AI, Reiter DA, Sekhar A, Sharma P, Safdar NM, Patil DH, Psutka SP, Small WC, Bilen MA, Ogan K, Master VA.

Appl Physiol Nutr Metab. 2019 Aug;44(8):814-819. doi: 10.1139/apnm-2018-0473. Epub 2019 Jan 7.

PMID:
30615474
17.

Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders.

Boilève A, Carlo MI, Barthélémy P, Oudard S, Borchiellini D, Voss MH, George S, Chevreau C, Landman-Parker J, Tabone MD, Chism DD, Amin A, Bilen MA, Bosse D, Coulomb-L'hermine A, Su X, Choueiri TK, Tannir NM, Malouf GG.

J Immunother Cancer. 2018 Dec 27;6(1):159. doi: 10.1186/s40425-018-0482-z.

18.

Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis.

Campbell MT, Bilen MA, Shah AY, Lemke E, Jonasch E, Venkatesan AM, Altinmakas E, Duran C, Msaouel P, Tannir NM.

Eur J Cancer. 2018 Nov;104:188-194. doi: 10.1016/j.ejca.2018.08.014. Epub 2018 Oct 28.

PMID:
30380460
19.

The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy.

Bilen MA, Martini DJ, Liu Y, Lewis C, Collins HH, Shabto JM, Akce M, Kissick HT, Carthon BC, Shaib WL, Alese OB, Pillai RN, Steuer CE, Wu CS, Lawson DH, Kudchadkar RR, El-Rayes BF, Master VA, Ramalingam SS, Owonikoko TK, Harvey RD.

Cancer. 2019 Jan 1;125(1):127-134. doi: 10.1002/cncr.31778. Epub 2018 Oct 17.

20.

The addition of chemotherapy in the definitive management of high risk prostate cancer.

Ferris MJ, Liu Y, Ao J, Zhong J, Abugideiri M, Gillespie TW, Carthon BC, Bilen MA, Kucuk O, Jani AB.

Urol Oncol. 2018 Nov;36(11):475-487. doi: 10.1016/j.urolonc.2018.07.020. Epub 2018 Oct 9. Review.

21.

Therapeutic Vaccines for Genitourinary Malignancies.

Dutcher GMA, Bilen MA.

Vaccines (Basel). 2018 Aug 12;6(3). pii: E55. doi: 10.3390/vaccines6030055. Review.

22.

Comparison of Outcomes in Patients With Muscle-invasive Bladder Cancer Treated With Radical Cystectomy Versus Bladder Preservation.

Zhong J, Switchenko J, Jegadeesh NK, Cassidy RJ, Gillespie TW, Master V, Nieh P, Alemozaffar M, Kucuk O, Carthon B, Filson CP, Bilen MA, Jani AB.

Am J Clin Oncol. 2019 Jan;42(1):36-41. doi: 10.1097/COC.0000000000000471.

23.

Metastatic Prostate Cancer Manifesting as Cholestatic Jaundice: A Case Report and Review of the Literature.

Ravindranathan D, Hitron EE, Russler GA, Xue Y, Bilen MA.

Case Rep Oncol Med. 2018 Mar 26;2018:1809432. doi: 10.1155/2018/1809432. eCollection 2018.

24.

Evaluation of programmed cell death protein 1 (PD-1) expression as a prognostic biomarker in patients with clear cell renal cell carcinoma.

Kim KS, Sekar RR, Patil D, Dimarco MA, Kissick HT, Bilen MA, Osunkoya AO, Master VA.

Oncoimmunology. 2018 Jan 10;7(4):e1413519. doi: 10.1080/2162402X.2017.1413519. eCollection 2018.

25.

Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.

Agarwal N, Pal SK, Hahn AW, Nussenzveig RH, Pond GR, Gupta SV, Wang J, Bilen MA, Naik G, Ghatalia P, Hoimes CJ, Gopalakrishnan D, Barata PC, Drakaki A, Faltas BM, Kiedrowski LA, Lanman RB, Nagy RJ, Vogelzang NJ, Boucher KM, Vaishampayan UN, Sonpavde G, Grivas P.

Cancer. 2018 May 15;124(10):2115-2124. doi: 10.1002/cncr.31314. Epub 2018 Mar 8.

26.

Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab.

Bilen MA, Dutcher GMA, Liu Y, Ravindranathan D, Kissick HT, Carthon BC, Kucuk O, Harris WB, Master VA.

Clin Genitourin Cancer. 2018 Jun;16(3):e563-e575. doi: 10.1016/j.clgc.2017.12.015. Epub 2018 Jan 4.

27.

A novel preoperative inflammatory marker prognostic score in patients with localized and metastatic renal cell carcinoma.

Sekar RR, Patil D, Baum Y, Pearl J, Bausum A, Bilen MA, Kucuk O, Harris WB, Carthon BC, Alemozaffar M, Filson CP, Pattaras JG, Nieh PT, Ogan K, Master VA.

Asian J Urol. 2017 Oct;4(4):230-238. doi: 10.1016/j.ajur.2017.04.002. Epub 2017 May 10.

28.

The prospects for combination therapy with capecitabine in the rapidly evolving treatment landscape of renal cell carcinoma.

Bilen MA, Carlisle JW, Sonpavde G.

Expert Opin Investig Drugs. 2018 Feb;27(2):163-170. doi: 10.1080/13543784.2018.1427731. Epub 2018 Jan 24. Review.

PMID:
29323560
29.

Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience.

Fujii T, Colen RR, Bilen MA, Hess KR, Hajjar J, Suarez-Almazor ME, Alshawa A, Hong DS, Tsimberidou A, Janku F, Gong J, Stephen B, Subbiah V, Piha-Paul SA, Fu S, Sharma P, Mendoza T, Patel A, Thirumurthi S, Sheshadri A, Meric-Bernstam F, Naing A.

Invest New Drugs. 2018 Aug;36(4):638-646. doi: 10.1007/s10637-017-0534-0. Epub 2017 Nov 21.

30.

Radiomics to predict immunotherapy-induced pneumonitis: proof of concept.

Colen RR, Fujii T, Bilen MA, Kotrotsou A, Abrol S, Hess KR, Hajjar J, Suarez-Almazor ME, Alshawa A, Hong DS, Giniebra-Camejo D, Stephen B, Subbiah V, Sheshadri A, Mendoza T, Fu S, Sharma P, Meric-Bernstam F, Naing A.

Invest New Drugs. 2018 Aug;36(4):601-607. doi: 10.1007/s10637-017-0524-2. Epub 2017 Oct 27.

31.

Frailty and cancer: Implications for oncology surgery, medical oncology, and radiation oncology.

Ethun CG, Bilen MA, Jani AB, Maithel SK, Ogan K, Master VA.

CA Cancer J Clin. 2017 Sep;67(5):362-377. doi: 10.3322/caac.21406. Epub 2017 Jul 21. Review.

32.

Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy.

Bilen MA, Hess KR, Subudhi SK, Aparicio A, Kim J, Zurita-Saavedra AJ, Araujo JC, Corn PG, Stover J, Lin SH, Logothetis CJ, Tu SM.

Cancer Chemother Pharmacol. 2017 Sep;80(3):583-589. doi: 10.1007/s00280-017-3391-9. Epub 2017 Jul 20.

PMID:
28730293
33.

Proteomics Profiling of Exosomes from Primary Mouse Osteoblasts under Proliferation versus Mineralization Conditions and Characterization of Their Uptake into Prostate Cancer Cells.

Bilen MA, Pan T, Lee YC, Lin SC, Yu G, Pan J, Hawke D, Pan BF, Vykoukal J, Gray K, Satcher RL, Gallick GE, Yu-Lee LY, Lin SH.

J Proteome Res. 2017 Aug 4;16(8):2709-2728. doi: 10.1021/acs.jproteome.6b00981. Epub 2017 Jul 18.

34.

Recent developments in the management of germ cell tumors.

Msaouel P, Bilen MA, Zhang M, Campbell M, Wang J, Tu SM.

Curr Opin Oncol. 2017 Feb 1. doi: 10.1097/CCO.0000000000000361. [Epub ahead of print]

35.

Safety of Same-day Pegfilgrastim Administration in Metastatic Castration-resistant Prostate Cancer Treated With Cabazitaxel With or Without Carboplatin.

Bilen MA, Cauley DH, Atkinson BJ, Chen HC, Kaya DH, Wang X, Vikram R, Tu SM, Corn PG, Kim J.

Clin Genitourin Cancer. 2017 Jun;15(3):e429-e435. doi: 10.1016/j.clgc.2016.12.003. Epub 2016 Dec 13.

36.

Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis.

Bilen MA, Hess KR, Campbell MT, Wang J, Broaddus RR, Karam JA, Ward JF, Wood CG, Choi SL, Rao P, Zhang M, Naing A, General R, Cauley DH, Lin SH, Logothetis CJ, Pisters LL, Tu SM.

Oncotarget. 2016 Dec 27;7(52):86280-86289. doi: 10.18632/oncotarget.13380.

37.

Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody.

Bilen MA, Subudhi SK, Gao J, Tannir NM, Tu SM, Sharma P.

J Immunother Cancer. 2016 Jun 21;4:36. doi: 10.1186/s40425-016-0139-8. eCollection 2016.

38.

Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials.

Bilen MA, Patel A, Hess KR, Munoz J, Busaidy NL, Wheler JJ, Janku F, Falchook GS, Hong DS, Meric-Bernstam F, Habra MA, Naing A.

Cancer Chemother Pharmacol. 2016 Jul;78(1):167-71. doi: 10.1007/s00280-016-3073-z. Epub 2016 Jun 10.

PMID:
27286994
39.

Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer.

Tu SM, Bilen MA, Hess KR, Broaddus RR, Kopetz S, Wei C, Pagliaro LC, Karam JA, Ward JF, Wood CG, Rao P, Tu ZH, General R, Chen AH, Nieto YL, Yeung SC, Lin SH, Logothetis CJ, Pisters LL.

Cancer. 2016 Jun 15;122(12):1836-43. doi: 10.1002/cncr.29996. Epub 2016 Mar 28.

40.

Personalised cancer care: promises and challenges of targeted therapy.

Tu SM, Bilen MA, Tannir NM.

J R Soc Med. 2016 Mar;109(3):98-105. doi: 10.1177/0141076816631154. Epub 2016 Mar 1. No abstract available.

41.

Cadherin-11 endocytosis through binding to clathrin promotes cadherin-11-mediated migration in prostate cancer cells.

Satcher RL, Pan T, Bilen MA, Li X, Lee YC, Ortiz A, Kowalczyk AP, Yu-Lee LY, Lin SH.

J Cell Sci. 2015 Dec 15;128(24):4629-41. doi: 10.1242/jcs.176081. Epub 2015 Oct 30.

42.

Hypertension and Circulating Cytokines and Angiogenic Factors in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Results From a Phase II Trial.

Bilen MA, Zurita AJ, Ilias-Khan NA, Chen HC, Wang X, Kearney AY, Hodges S, Jonasch E, Huang S, Khakoo AY, Tannir NM.

Oncologist. 2015 Oct;20(10):1140-8. doi: 10.1634/theoncologist.2015-0143. Epub 2015 Aug 25.

43.

Radium-223: Optimizing Treatment and Research of Osteoblastic Bone Metastasis.

Tu SM, Bilen MA, Lin SH.

Oncology (Williston Park). 2015 Jul;29(7):490-2. No abstract available.

44.

Maintenance Therapy Containing Metformin and/or Zyflamend for Advanced Prostate Cancer: A Case Series.

Bilen MA, Lin SH, Tang DG, Parikh K, Lee MH, Yeung SC, Tu SM.

Case Rep Oncol Med. 2015;2015:471861. doi: 10.1155/2015/471861. Epub 2015 Mar 15.

45.

Phase I trial of valproic acid and lenalidomide in patients with advanced cancer.

Bilen MA, Fu S, Falchook GS, Ng CS, Wheler JJ, Abdelrahim M, Erguvan-Dogan B, Hong DS, Tsimberidou AM, Kurzrock R, Naing A.

Cancer Chemother Pharmacol. 2015 Apr;75(4):869-74. doi: 10.1007/s00280-015-2695-x. Epub 2015 Feb 10.

PMID:
25666183
46.

Angiomotin is a novel component of cadherin-11/β-catenin/p120 complex and is critical for cadherin-11-mediated cell migration.

Ortiz A, Lee YC, Yu G, Liu HC, Lin SC, Bilen MA, Cho H, Yu-Lee LY, Lin SH.

FASEB J. 2015 Mar;29(3):1080-91. doi: 10.1096/fj.14-261594. Epub 2014 Dec 2.

47.

Variant prostate carcinoma and elevated serum CA-125.

Bilen MA, Reyes A, Bhowmick D, Maa A, Bast R Jr, Pisters LL, Lin SH, Logothetis CJ, Tu SM.

Can J Urol. 2014 Oct;21(5):7442-8.

48.

Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer.

Bilen MA, Johnson MM, Mathew P, Pagliaro LC, Araujo JC, Aparicio A, Corn PG, Tannir NM, Wong FC, Fisch MJ, Logothetis CJ, Tu SM.

Cancer. 2015 Jan 1;121(1):69-76. doi: 10.1002/cncr.28971. Epub 2014 Aug 22.

49.

Evaluation of a novel blood pressure scoring method and its association with clinical response in cancer patients treated with anti-vascular endothelial growth factor therapy.

Bilen MA, Durand JB, McQuinn L, Hess KR, Fu S, Falchook GS, Hong DS, Wheler JJ, Said R, Ewer MS, Kurzrock R, Naing A.

Invest New Drugs. 2014 Aug;32(4):717-22. doi: 10.1007/s10637-014-0104-7. Epub 2014 Apr 26.

PMID:
24764123
50.

The scientific method: pillar and pitfall of cancer research.

Tu SM, Bilen MA, Tannir NM.

Cancer Med. 2014 Aug;3(4):1035-7. doi: 10.1002/cam4.248. Epub 2014 Apr 8. No abstract available.

Supplemental Content

Loading ...
Support Center